UNSPSC 51281504: Pyrazinamide

This classification denotes an antitubercular agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2KNI5N06TI. European Medicines Agency schedules Pyrazinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10163MIG. Pyrazinamide generally arises in the molecular formula C5H5N3O.

The term PYRAZINAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) PYRAZINAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pyrazinamide under HS 29339990 and SITC 51577. As of Q4 2014, PYRAZINAMIDE remains the US FDA Preferred Term for this commodity. Pyrazinamide bears US NLM identifiers UMLS ID C0034239 and NCI Concept Code C29395. SMILES: O=C(N)C1NCCNC1.

UNSPSC 51281504 Pyrazinamide, a Commodity code, sees little relevant recent activity. The code nominally describes a specific tuberculosis antibiotic, yet the recent solicitations tagged to it span naloxone kits, emergency medical supplies, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals—none of which are pyrazinamide or directly related to it. The mismatch suggests either upstream classification error or that the code is being used as a catch-all for pharmaceutical and medical supply procurement outside its intended scope. State and local buyers do procure pharmaceuticals and medical consumables regularly, but the recent opportunities attributed to this code do not reflect pyrazinamide demand specifically.

The issuing bodies in the recent records include Seminole County, Florida (health department naloxone procurement); the City of Tampa (fire department medical and first aid supplies via IFB); the Texas Health and Human Services Commission (exploratory RFI on direct-to-manufacturer pharmacy programs); and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic multi-source pharmaceuticals and OTC products). The geographic spread covers Florida, Texas, Minnesota, and Oregon, with activity spanning county health departments, municipal fire services, and cooperative purchasing vehicles. The representative opportunities are the Seminole County IFB for 1,900 units of naloxone and 800 safe drug deactivation systems (due July 26, 2023); the City of Tampa IFB for 169 line items of medical and first aid supplies estimated at $700,000 (due March 13, 2026, sheltered for certified Small Local Business Enterprises with a 5% bid discount); and the MMCAP RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline. The Texas HHS RFI issued April 3, 2026 represents preliminary market research rather than an active procurement opportunity. No recent opportunities directly solicit pyrazinamide or tuberculosis medications.